综述:间充质基质细胞治疗炎症性肠病
本综述检索PubMed与ClinicalTrials.gov数据库,汇总间充质基质细胞(MSC)治疗炎症性肠病的数据。局部注射治疗难治性瘘管患者超过200例,完全缓解超过半数、总体缓解约三分之二;难治性管腔型克罗恩病全身输注49例,异体MSC约60%应答、约40%临床缓解。MSC可能是有前景的疗法,但来源、剂量与给药方式等问题待解,尚需随机对照试验证实。
要点
- 局部注射MSC治疗难治性瘘管超过200例,完全缓解超过半数,总体缓解约三分之二。
- 难治性管腔型克罗恩病全身输注MSC报告49例,异体MSC约60%应答、约40%临床缓解。
- MSC的起源与来源、剂量及给药方式等许多问题尚未解决,尚需随机对照试验证实疗效。
核心结论
- 间充质基质细胞可能代表炎症性肠病尤其是克罗恩病的一种有前景的疗法。
- 关于间充质基质细胞最佳起源与来源、剂量及给药方式仍有许多未解决的问题。
- 间充质基质细胞仍需在随机对照试验中证明其相较于常规治疗的有效性。
研究设计与样本
- 综述,检索PubMed与ClinicalTrials.gov数据库,检索词为「间充质基质细胞」「间充质干细胞移植」「炎症性肠病」「克罗恩病」「溃疡性结肠炎」。
- 从单篇文献的参考文献列表中补充识别额外文献。
主要发现
- MSC可抑制Th1/Th17淋巴细胞并招募调节性T淋巴细胞,诱导抗原提呈细胞向调节样表型转化,并刺激上皮细胞分化与增殖。
- 超过200例难治性瘘管患者接受局部注射MSC治疗,超过半数达完全缓解,约三分之二达总体缓解。
- 难治性管腔型克罗恩病中报告49例全身输注MSC,自体MSC试验应答减弱,而异体MSC研究结果有前景,约60%患者出现应答、约40%达到临床缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 关于间充质基质细胞最佳起源与来源、剂量及给药方式仍有许多未解决的问题。
- 间充质基质细胞仍需在随机对照试验中证明其相较于常规治疗的有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammatory bowel diseases (IBD) are chronic relapsing diseases in which pro-inflammatory immune cells and cytokines induce intestinal tissue damage and disability. Mesenchymal stromal cells (MSCs) exert powerful immunomodulatory effects and stimulate tissue repair. AIM: To review the current data on mesenchymal stromal cell therapy in IBD. METHOD: We searched PubMed and 'ClinicalTrials.gov' databases using the terms 'mesenchymal stromal cells', 'mesenchymal stem cell transplantation', 'inflammatory bowel diseases', 'Crohn disease' and 'colitis, ulcerative'. Additional publications were identified from individual article reference lists. RESULTS: MSCs include inhibition of Th1/Th17 lymphocytes and recruitment of regulatory T lymphocytes, induction of antigen-presenting cells into a regulatory-like profile, and stimulation of epithelial cell differentiation and proliferation. More than 200 patients with refractory fistulas have been treated with local injections of MSCs, resulting in complete response in more than half, and in overall response in approximately two thirds of patients. In refractory luminal Crohn's disease, 49 cases of systemic MSC infusions have been reported, while trials with autologous MSCs resulted in mitigated responses, studies using allogeneic MSCs were promising, with around 60% of patients experiencing a response and around 40% achieving clinical remission. CONCLUSIONS: Mesenchymal stromal cells might represent a promising therapy for IBD, especially for Crohn's disease. There remain many unsolved questions concerning the optimal origin and source of mesenchymal stromal cells, dosage and modalities of administration. Moreover, mesenchymal stromal cells still need to prove their effectiveness compared with conventional treatments in randomised controlled trials.
引用
- Grégoire C, Lechanteur C, Briquet A, et al. Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Aliment Pharmacol Ther. 2016. PMID: 27878827. doi:10.1111/apt.13864
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。